http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505503.html si-local-file:///var/storage/secattach/20260515/26505503.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505503.html Fri, 15 May 2026 16:16:00 -0400 FHTX O.49002690 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505503.html si-local-file:///var/storage/secattach/20260515/26505503.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505503.html Fri, 15 May 2026 16:16:00 -0400 FHTX O.49002690 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+Flynn+James+E/26497111.html si-local-file:///var/storage/secattach/20260514/26497111.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+Flynn+James+E/26497111.html Thu, 14 May 2026 18:20:00 -0400 FHTX O.49002690 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+Flynn+James+E/26497111.html si-local-file:///var/storage/secattach/20260514/26497111.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Foghorn+Therapeutics+++++++++++++++++++Filed+by%3A+Flynn+James+E/26497111.html Thu, 14 May 2026 18:20:00 -0400 FHTX O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html <p>WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO &amp; EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.</p> http://www.streetinsider.com/Globe+Newswire/Foghorn+Therapeutics+to+Participate+in+Three+Upcoming+Investor+Conferences+in+May/26472657.html Tue, 12 May 2026 07:00:00 -0400 A.50100012 A.50205019 FHTX O.00706867 O.07579093 O.49002690 http://www.streetinsider.com/Earnings/Foghorn+Therapeutics+Inc.+%28FHTX%29+Misses+Q1+EPS+by+1c/26448498.html <p>Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q1 EPS of ($0.29), $0.01 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $3.26 million versus the consensus estimate of $9.35 million.</p><p>For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=FHTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Foghorn+Therapeutics+Inc.+%28FHTX%29+Misses+Q1+EPS+by+1c/26448498.html Thu, 07 May 2026 07:44:43 -0400 FHTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Foghorn+Therapeutics++++++For%3A+Mar+31/26447942.html si-local-file:///var/storage/secattach/20260507/26447942.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Foghorn+Therapeutics++++++For%3A+Mar+31/26447942.html Thu, 07 May 2026 07:03:00 -0400 FHTX O.49002690 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Foghorn+Therapeutics++++++For%3A+Mar+31/26447942.html si-local-file:///var/storage/secattach/20260507/26447942.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Foghorn+Therapeutics++++++For%3A+Mar+31/26447942.html Thu, 07 May 2026 07:03:00 -0400 FHTX O.49002690 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Foghorn+Therapeutics++++++For%3A+May+07/26447926.html si-local-file:///var/storage/secattach/20260507/26447926.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Foghorn+Therapeutics++++++For%3A+May+07/26447926.html Thu, 07 May 2026 07:02:00 -0400 FHTX O.49002690 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Foghorn+Therapeutics++++++For%3A+May+07/26447926.html si-local-file:///var/storage/secattach/20260507/26447926.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Foghorn+Therapeutics++++++For%3A+May+07/26447926.html Thu, 07 May 2026 07:02:00 -0400 FHTX O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html <p align="center"><em>- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory </em></p> <p align="center"><em>- Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027</em></p> <p align="center"><em>-Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027</em></p> <p align="center"><em>- Strong balance sheet with cash, cash equivalents, and marketable securities of approximately </em><em>$184 million</em><em>; cash runway into the first half of 2028</em><br/></p> <p>WATERTOWN, Mass., May 07, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html Thu, 07 May 2026 07:00:00 -0400 A.35552990 A.50205019 FHTX O.00074346 O.00706867 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html <p align="center"><em>- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory </em></p> <p align="center"><em>- Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027</em></p> <p align="center"><em>-Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027</em></p> <p align="center"><em>- Strong balance sheet with cash, cash equivalents, and marketable securities of approximately </em><em>$184 million</em><em>; cash runway into the first half of 2028</em><br/></p> <p>WATERTOWN, Mass., May 07, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html Thu, 07 May 2026 07:00:00 -0400 A.35552990 A.50205019 FHTX O.00074346 O.00706867 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html <p align="center"><em>- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory </em></p> <p align="center"><em>- Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027</em></p> <p align="center"><em>-Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027</em></p> <p align="center"><em>- Strong balance sheet with cash, cash equivalents, and marketable securities of approximately </em><em>$184 million</em><em>; cash runway into the first half of 2028</em><br/></p> <p>WATERTOWN, Mass., May 07, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html Thu, 07 May 2026 07:00:00 -0400 A.35552990 A.50205019 FHTX O.00074346 O.00706867 O.49002690 http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html <p align="center"><em>- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory </em></p> <p align="center"><em>- Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027</em></p> <p align="center"><em>-Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027</em></p> <p align="center"><em>- Strong balance sheet with cash, cash equivalents, and marketable securities of approximately </em><em>$184 million</em><em>; cash runway into the first half of 2028</em><br/></p> <p>WATERTOWN, Mass., May 07, 2026 (GLOBE http://www.streetinsider.com/Press+Releases/Foghorn+Therapeutics+Provides+First+Quarter+2026+Financial+and+Corporate+Update/26447838.html Thu, 07 May 2026 07:00:00 -0400 A.35552990 A.50205019 FHTX O.00074346 O.00706867 O.49002690